Products/Services Used | Details | Operation |
---|---|---|
CRISPR Libraries> | … with raising $423.84 million in US IPO, was the biggest winner in 2020, which also emerged as one of the largest public raises in biotech … in 2018; and (5) MilliporeSigma establishing a strategic alliance with GenScript focusing on the manufacturing of CGTs in 2019. CAR-T cell … | Get A Quote |
Chimeric antigen receptor T (CAR-T) cell therapy achieved extraordinary achievements results in antitumor treatments, especially against hematological malignancies, where it leads to remarkable, long-term antineoplastic effects with higher target specificity. Nevertheless, some limitations persist in autologous CAR-T cell therapy, such as high costs, long manufacturing periods, and restricted cell sources. The development of a universal CAR-T (UCAR-T) cell therapy is an attractive breakthrough point that may overcome most of these drawbacks. Here, we review the progress and challenges in CAR-T cell therapy, especially focusing on comprehensive comparison in UCAR-T cell therapy to original CAR-T cell therapy. Fu... More